Endocrinology

August 18th 2025

Michael Haller, MD, discusses inhaled insulin’s safety, off-label use, and future role in easing type 1 diabetes management for children.

August 14th 2025

Richard Auchus, MD, PhD, discusses how crinecerfont is improving CAH care and easing the transition from pediatric to adult management.

July 8th 2025

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

June 9th 2025

The combination therapy yielded boosted treatment benefits of navepegritide, including improvement in mean ACH Z-score and mean annualized growth.